Following on from information provided to NICE by the company in April 2014, the appraisal of Pazopanib for the maintenance treatment of epithelial ovarian, fallopian and peritoneal cancer [ID545] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
| Status | Discontinued |
| Technology type | Medicine |
| Decision | Selected |
| Process | TA |
| ID number | 545 |
| Referral date | 01 October 2013 |
| Topic area |
|
Provisional Schedule
| Closing date for invited submissions / evidence submission: | TBC |
| 1st appraisal committee meeting: | TBC |
Project Team
| Communications manager: | TBC |
| Executive Lead: | TBC |
| Project manager: | TBC |
| Technical Lead: | TBC |
Email enquiries
- If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 31 October 2022 | Following on from information provided to NICE by the company in April 2014, the appraisal of Pazopanib for the maintenance treatment of epithelial ovarian, fallopian and peritoneal cancer [ID545] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 31 October 2022 | Discontinued. Following on from information provided to NICE by the company in April 2014, the appraisal of Pazopanib for the maintenance treatment of epithelial ovarian, fallopian and peritoneal cancer [ID545] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 14 April 2014 |
As you will be aware, the Department of Health has asked the Institute to conduct an appraisal of pazopanib for the maintenance treatment of epithelial ovarian, fallopian and peritoneal cancer in patients whose disease has not progressed after first line therapy . The Institute has now been informed by the manufacturer that it will no longer be pursuing a licensing application for pazopanib in this indication, therefore, NICE has decided to suspend this appraisal on its current work programme. As this topic has been referred to the Institute we will continue to monitor any development and will update interested parties if the situation changes. |
For further information on our processes and methods, please see our CHTE processes and methods manual